Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine‐Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX‐BC Study)

LESSONS LEARNED: Axitinib exhibited marginal activity against gemcitabine‐refractory unselected biliary tract cancer. Pretreated soluble vascular endothelial growth factor receptor‐2 may be a useful biomarker for axitinib treatment outcome. Ascites should be carefully monitored in patients receiving...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncologist
Auteurs principaux: Okano, Naohiro, Furuse, Junji, Ueno, Makoto, Morizane, Chigusa, Yamanaka, Takeharu, Ojima, Hidenori, Ozaka, Masato, Sasaki, Mitsuhito, Takahara, Naminatsu, Nakai, Yousuke, Kobayashi, Satoshi, Morimoto, Manabu, Hosoi, Hiroko, Maeno, Satoko, Nagashima, Fumio, Ikeda, Masafumi, Okusaka, Takuji
Format: Artigo
Langue:Inglês
Publié: John Wiley & Sons, Inc. 2020
Sujets:
Clinical Trial Results
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873316/
https://ncbi.nlm.nih.gov/pubmed/33010112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13547
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires